1. Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study. Issue 3 (30th January 2023) Authors: Kim, Dae Jung; Sheu, Wayne H‐H; Chung, Wook‐Jin; Yabe, Daisuke; Ha, Kyoung Hwa; Nangaku, Masaomi; Tan, Elise Chia‐Hui; Node, Koichi; Yasui, Atsutaka; Lei, Weiyu; Lee, Sunwoo; Saarelainen, Laura; Deruaz‐Luyet, Anouk; Kyaw, Moe H; Seino, Yutaka Journal: Journal of diabetes investigation Issue: Volume 14:Issue 3(2023) Page Start: 417 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗